Hutter Sonja, Bolin Sara, Weishaupt Holger, Swartling Fredrik J
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden.
Genes (Basel). 2017 Mar 23;8(4):107. doi: 10.3390/genes8040107.
Brain tumors are the second most common group of childhood cancers, accounting for about 20%-25% of all pediatric tumors. Deregulated expression of the MYC family of transcription factors, particularly - and genes, has been found in many of these neoplasms, and their expression levels are often correlated with poor prognosis. Elevated c-MYC/MYCN initiates and drives tumorigenesis in many model systems of pediatric brain tumors. Therefore, inhibition of their oncogenic function is an attractive therapeutic target. In this review, we explore the roles of MYC oncoproteins and their molecular targets during the formation, maintenance, and recurrence of childhood brain tumors. We also briefly summarize recent progress in the development of therapeutic approaches for pharmacological inhibition of MYC activity in these tumors.
脑肿瘤是儿童癌症中第二常见的类型,约占所有儿科肿瘤的20%-25%。在许多这类肿瘤中发现了转录因子MYC家族的表达失调,尤其是 和 基因,并且它们的表达水平通常与预后不良相关。在许多儿科脑肿瘤模型系统中,c-MYC/MYCN的升高启动并驱动肿瘤发生。因此,抑制它们的致癌功能是一个有吸引力的治疗靶点。在这篇综述中,我们探讨了MYC癌蛋白及其分子靶点在儿童脑肿瘤形成、维持和复发过程中的作用。我们还简要总结了在开发针对这些肿瘤中MYC活性进行药理抑制的治疗方法方面的最新进展。